Sage Therapeutics Inc
(FRA:SG7)
€
5.79
-0.394 (-6.37%)
Market Cap: 328.82 Mil
Enterprise Value: -195.46 Mil
PE Ratio: 0
PB Ratio: 0.70
GF Score: 45/100 SAGE Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2022 / 03:30PM GMT
Release Date Price:
€34.02
(+1.76%)
Akash Tewari
Jefferies LLC, Research Division - Equity Analyst
For those of you who don't know me, my name is Akash Tewari. I am a biotech analyst here at Jefferies. Today, I have the pleasure of hosting the Sage management team. Joining us today are Kimi Iguchi, Jim Doherty and Chris Benecchi. And we are going to...
Kimi E. Iguchi
Sage Therapeutics, Inc. - CFO & Treasurer
Albert Robichaud. He was not able to make it today.
Akash Tewari
Jefferies LLC, Research Division - Equity Analyst
Okay, my mistake. But either way, it's great to have you guys. That is true. So why don't we start off with heading into Kimi to give some brief introductory remarks, and then we'll get into our set of questions.
Kimi E. Iguchi
Sage Therapeutics, Inc. - CFO & Treasurer
Great. Terrific. Thanks, Akash, and thanks for having us to the conference. We're excited to be here. I'm excited to be in Manhattan, it's been a while. But for those of you who aren't familiar with Sage, Sage is
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot